# Merck & Co., Inc. (NYSE: MRK)

## Company Overview

**Type:** Public Company
**Stock Ticker:** MRK (NYSE)
**Market Cap:** $265.03 billion (as of December 2025)
**Headquarters:** Rahway, New Jersey, USA
**Industry:** Pharmaceuticals & Healthcare
**NYSE Listing:** Since 1927

Merck & Co., Inc. is a global healthcare company that discovers, develops, manufactures, and markets a broad range of human and animal health products. The company is recognized as one of the world's leading pharmaceutical companies, with Keytruda becoming one of the highest-selling pharmaceutical products of all time.

---

## Financial Performance

### Annual Financial Summary (2022-2024)

| Year | Revenue | Net Income | Net Profit Margin | YoY Revenue Growth |
|------|---------|------------|-------------------|-------------------|
| 2022 | $59.283B | $14.524B | ~24.5% | - |
| 2023 | $60.115B | $0.365B | ~0.6% | 1.4% |
| 2024 | $64.168B | $17.117B | ~26.7% | 6.74% |

**Note:** The significant net income decline in 2023 appears related to one-time charges or events, with strong recovery in 2024.

### Quarterly Financial Performance (2023-2025)

#### 2023 Quarterly Results
| Quarter | Revenue | YoY Growth |
|---------|---------|------------|
| Q4 2023 | $14.6B | 6% |
| Full Year 2023 | $60.1B | 1% |

#### 2024 Quarterly Results
| Quarter | Revenue | YoY Growth |
|---------|---------|------------|
| Q1 2024 | $15.8B | 9% |
| Q3 2024 | $16.7B | 4% |
| Q4 2024 | $15.6B | 7% |
| Full Year 2024 | $64.2B | 7% (10% excluding FX impact) |

**Full-Year 2024 Highlights:**
- Non-GAAP EPS: $7.65
- Q4 2024 Non-GAAP EPS: $1.72

#### 2025 Quarterly Results (Available)
| Quarter | Revenue |
|---------|---------|
| Q1 2025 | $15.5B |

---

## Product Portfolio

### Key Products Performance (2024-2025)

#### 1. **Keytruda (pembrolizumab)** - Flagship Oncology Product
- **2024 Sales:** $29.5 billion (+18% YoY)
- **Market Position:** World's top-selling cancer drug
- **2025 Q3 Sales:** $8.1 billion (+10% nominal, +8% excluding FX)
- **Approvals:** 20 different types of cancer
- **Key Milestone:** FDA approved KEYTRUDA QLEX (subcutaneous injection) in September 2025
  - Administration time: Under 2 minutes vs. 30-minute IV infusion
  - Approved for adults across most solid tumor indications

#### 2. **Gardasil/Gardasil 9** - HPV Vaccines
- **2024 Sales:** $8.6 billion (-3% YoY)
- **2025 Q2 Sales:** $1.1 billion (-55%)
- **2025 Q3 Sales:** $1.7 billion (-24% nominal, -25% excluding FX)
- **Performance Notes:** Significant decline due to reduced demand in China; double-digit growth outside China in most major regions

#### 3. **Januvia/Janumet** - Diabetes Treatments
- **2024 Januvia Sales:** $1.33 billion (-39.1%)
- **2024 Janumet Sales:** $935 million (-16.3%)
- **Challenges:** Lower U.S. pricing and generic competition in international markets

### Pipeline & Milestones

**Pipeline Value:** 20 potential new blockbuster drugs with estimated $50+ billion in future revenue potential

**Recent FDA Approvals & Regulatory Milestones (2024-2025):**

1. **Oncology:**
   - KEYTRUDA QLEX subcutaneous formulation approved (September 2025)
   - European Commission approval for KEYTRUDA + chemotherapy for metastatic malignant pleural mesothelioma
   - WELIREG conditional EC approval (first oral HIF-2α inhibitor in EU)
   - Priority Review granted for KEYTRUDA + SOC for LA-HNSCC (PDUFA: June 23, 2025)
   - Breakthrough Therapy designation for sacituzumab tirumotecan (sac-TMT) for EGFR-mutated NSCLC

2. **Vaccines:**
   - BLA accepted for clesrovimab (RSV prophylaxis for infants) with PDUFA date of June 10, 2025

**Pipeline Updated:** November 3, 2025

---

## Revenue by Geography (2024)

| Region | Revenue | % of Total |
|--------|---------|------------|
| United States | $32.28B | ~50.3% |
| EMEA (Europe, Middle East, Africa) | $14.04B | 21.88% |
| China | $5.49B | 8.55% |
| Japan | $3.28B | 5.11% |
| Asia Pacific | $3.06B | 4.77% |
| International | $2.56B | 3.99% |
| **Total** | **$64.2B** | **100%** |

**Key Insights:**
- United States remains the largest market at approximately 50% of total revenue
- International markets collectively account for the remaining 50%
- Growth of 7% overall (10% excluding foreign exchange impact)

---

## Key Annual Events

Merck regularly participates in major healthcare and investor events to showcase products and research:

1. **J.P. Morgan Healthcare Conference**
   - 43rd Annual Conference: January 13, 2025
   - Participants: Robert M. Davis (CEO) and Dr. Dean Y. Li (EVP, President of Merck Research Laboratories)

2. **ASCO (American Society of Clinical Oncology) Annual Meeting**
   - Investor Event scheduled: June 2, 2025
   - Platform for presenting oncology research and pipeline advances

3. **ESMO (European Society for Medical Oncology) Congress**
   - Regular participation for European oncology market updates

4. **Quarterly Earnings Calls**
   - Regular investor communications and financial updates

---

## Competitors & Market Differentiation

### Main Competitors (2025 Rankings by Revenue)

| Rank | Company | 2024 Revenue | Key Notes |
|------|---------|--------------|-----------|
| 1 | **Merck** | $64.17B | Leader in oncology immunotherapy |
| 2 | **Pfizer** | $63.63B | Diversified portfolio with Eliquis, Prevnar, Vyndaqel |
| 3 | **Johnson & Johnson** | $57.07B | Strong in oncology and immunology |
| 4 | **AbbVie** | $56.33B | Skyrizi ($11.7B) and Rinvoq ($6.0B) growth offsetting Humira decline |
| 5 | **Novartis** | $50.3B | 12% growth in net pharma sales |
| - | **Bristol Myers Squibb** | - | Key competitor in immunotherapy (Opdivo) |

### Merck's Competitive Differentiation Strategies

#### 1. **Keytruda vs. Opdivo (Bristol Myers Squibb)**

**Strategic Advantages:**
- **Biomarker-Targeted Approach:** Enrolled patients with PD-L1 expression ≥50%, designed longer trials with more patients, demonstrated survival benefit vs. chemotherapy while BMS trials failed
- **First-to-Market:** FDA accelerated approval for melanoma on September 4, 2014 (3+ months ahead of Opdivo)
- **Broader Indications:** 20 cancer type approvals vs. Opdivo's narrower scope
- **Combination Therapy Excellence:** Keytruda + chemotherapy combinations proved more successful than BMS's Opdivo + Yervoy strategy
- **Innovation in Delivery (2025):** KEYTRUDA QLEX subcutaneous formulation (2-minute injection vs. 30-minute IV) provides competitive edge over IV-only rivals

**Market Performance:**
- Keytruda: $29.5B (2024) - world's top-selling cancer drug
- Opdivo's sales eclipsed by Keytruda due to rapid first-line therapy adoption

#### 2. **Overall Differentiation Strategy**

**Strengths:**
- **R&D Leadership:** $50+ billion pipeline of 20 potential blockbusters
- **Oncology Dominance:** Keytruda franchise continues expansion into new indications
- **Strategic Trial Design:** Focus on biomarker-driven patient selection proved superior
- **Innovation in Formulations:** Subcutaneous delivery reduces healthcare costs and improves patient convenience

**Challenges:**
- HPV vaccine market facing headwinds in China
- Diabetes franchise declining due to pricing pressure and generic competition
- Industry-wide challenges: Patent cliffs, Medicare Part D redesign, Chinese market volatility

---

## Key Insights

1. **Market Leadership:** Merck maintained its position as the largest pharmaceutical company in 2025 with ~$64.17B in revenue
2. **Keytruda Dominance:** The flagship product represents nearly 46% of total revenue and continues double-digit growth
3. **Geographic Diversification:** Balanced 50/50 split between U.S. and international markets
4. **Innovation Focus:** Strong pipeline with $50B+ potential from 20 blockbuster candidates
5. **Competitive Moat:** Strategic biomarker-driven trial design and first-to-market execution created sustainable advantage in oncology immunotherapy

---

**Last Updated:** December 31, 2025

## Sources

- [Merck & Co., Inc. (MRK) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/MRK/)
- [Merck Revenue - MacroTrends](https://www.macrotrends.net/stocks/charts/MRK/merck/revenue)
- [Merck Net Income - MacroTrends](https://www.macrotrends.net/stocks/charts/MRK/merck/net-income)
- [Merck Net Profit Margin - MacroTrends](https://www.macrotrends.net/stocks/charts/MRK/merck/net-profit-margin)
- [Merck Q1 2024 Earnings Report](https://www.merck.com/stories/our-q1-2024-earnings-report/)
- [Merck Q4 and Full-Year 2024 Financial Results](https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/)
- [Merck Q3 2024 Financial Results](https://www.merck.com/stories/our-q3-2024-financial-results/)
- [Merck Q3 2025 Financial Results](https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2025-financial-results/)
- [Merck Q2 2025 Financial Results](https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-announces-second-quarter-2025-financial-results/)
- [Merck's Top-Selling Drugs - Statista](https://www.statista.com/statistics/272367/revenues-of-merck-and-co-top-selling-drugs/)
- [Merck 2025: Keytruda and? - PharmaLive](https://www.pharmalive.com/merck-co-2025-keytruda-and/)
- [Merck Revenue Breakdown by Region - Bullfincher](https://bullfincher.io/companies/merck-co/revenue-by-geography)
- [Merck Revenue by Region 2019-2023 - Statista](https://www.statista.com/statistics/380844/revenues-of-merck-and-co-by-region/)
- [Top 10 Pharmaceutical Companies Worldwide (2025) - Proclinical](https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2025)
- [Pharma 50: Top Pharma Companies 2025 - Drug Discovery and Development](https://www.drugdiscoverytrends.com/pharma-50-the-50-largest-pharmaceutical-companies-in-the-world-for-2025/)
- [Merck Pipeline](https://www.merck.com/research/product-pipeline/)
- [Merck Pipeline 2Q2025](https://www.merck.com/wp-content/uploads/sites/124/2025/05/Public-Pipeline-2Q2025.pdf)
- [Merck Touts 20 New Blockbuster Drugs - Fortune Well](https://fortune.com/well/2025/02/04/merck-touts-new-blockbuster-drugs-50-billion-potential/)
- [Research at ASCO 2025 - Merck](https://www.merck.com/news/research-on-novel-treatment-approaches-and-scientific-advances-from-mercks-broad-and-differentiated-oncology-portfolio-and-pipeline-to-be-presented-at-asco-2025/)
- [Merck at 43rd Annual J.P. Morgan Healthcare Conference](https://www.merck.com/news/merck-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference/)
- [JP Morgan Healthcare Conference Presentation - January 13, 2025](https://s21.q4cdn.com/488056881/files/doc_events/2025/Jan/13/MRK-JP-Morgan-Presentation-FINAL-1-13-25.pdf)
- [Keytruda vs. Opdivo Analysis - Science AAAS](https://www.science.org/content/blog-post/keytruda-vs-opdivo-no-contest)
- [Decade of Cancer Immunotherapy - BioPharma Dive](https://www.biopharmadive.com/news/cancer-immunotherapy-decade-keytruda-opdivo-pd1-oncology/725774/)
- [Merck's Keytruda Qlex Strategic Leap - AInvest](https://www.ainvest.com/news/merck-keytruda-qlex-strategic-leap-competitive-differentiation-oncology-market-expansion-2509/)
